Document Classification

Section Type: RESULTS

Text: After 48 weeks of study treatment the patients assigned to the triple-combination regimen (nevirapine, zidovudine, and didanosine) had an 18 % higher mean absolute CD4 cell count (95 % Cl, 7 % to 29 % ; P = 0. 001), a 0. 32 log10 lower mean infectious HIV-1 titer in peripheral blood mononuclear cells (Cl, 0. 05 to 0. 59 log10 infectious units per million cells ; P = 0. 023), and a 0. 25 log10 lower mean plasma HIV-1 RNA level (Cl, 0. 03 to 0. 48 log10 RNA copies/mL ; P = 0. 028) than did patients assigned to the double-combination regimen (zidovudine and didanosine).